1. Home
  2. MLYS vs EMAT Comparison

MLYS vs EMAT Comparison

Compare MLYS & EMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$25.85

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Evolution Metals & Technologies Corp. Common Stock

EMAT

Evolution Metals & Technologies Corp. Common Stock

HOLD

Current Price

$3.15

Market Cap

2.6B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
EMAT
Founded
2019
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
MLYS
EMAT
Price
$25.85
$3.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
1
Target Price
★ $48.67
$30.00
AVG Volume (30 Days)
★ 1.2M
1.2M
Earning Date
05-06-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 37.43
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2,122.43
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.30
$2.15
52 Week High
$47.65
$17.50

Technical Indicators

Market Signals
Indicator
MLYS
EMAT
Relative Strength Index (RSI) 39.48 44.52
Support Level $22.36 $2.95
Resistance Level $31.36 $4.73
Average True Range (ATR) 1.48 0.47
MACD -0.40 -0.01
Stochastic Oscillator 5.09 11.11

Price Performance

Historical Comparison
MLYS
EMAT

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About EMAT Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp is a critical materials and technology company. The company is focused on developing a secure, dependable, and self-sustaining U.S.-aligned supply chain for critical minerals and materials (CMM), and rare earth elements (REEs). The company is also engaged in recycling end-of-life materials through urban mining to help strengthen domestic resource independence and long-term supply stability.

Share on Social Networks: